Lidocaína Aurovitas (Lidocaine Hydrochloride)

Lidocaína Aurovitas is a local anesthetic used in procedures that require temporary nerve blockade.

• Epidural procedures: provides localized anesthesia for obstetric or surgical interventions performed via the epidural space.
• Intramuscular injections: produces rapid, site‑specific numbness to facilitate painful intramuscular drug administration.
• Intravenous regional anesthesia (Bier block): enables safe, reversible anesthesia of a limb during minor orthopedic surgeries.
• Pain management: offers short‑term analgesia for acute procedural pain when administered by qualified clinicians.

• Lidocaine Hydrochloride exerts its effect by reversibly binding to voltage‑gated sodium channels on neuronal membranes, stabilizing the inactive state of the channel. This blockade prevents the influx of sodium ions required for depolarization, thereby inhibiting the initiation and propagation of nerve impulses and producing localized loss of sensation.

Lidocaína Aurovitas may cause a range of adverse reactions, most of which are related to its local anesthetic properties.

Common Side Effects

• Transient numbness or tingling at the injection site
• Mild hypotension or dizziness
• Nausea or metallic taste
• Localized swelling or erythema
• Headache
• Mild pruritus

Serious or Rare Side Effects

• Allergic reactions including rash, urticaria or anaphylaxis
• Central nervous system toxicity such as seizures or loss of consciousness
• Cardiac arrhythmias or conduction disturbances
• Methemoglobinemia
• Respiratory depression
• Systemic toxicity with CNS and cardiovascular collapse

When using Lidocaína Aurovitas, clinicians should observe several safety measures.

• Assess patient allergy: verify no known hypersensitivity to lidocaine or amide‑type anesthetics.
• Monitor cardiovascular status: watch for hypotension, bradycardia or arrhythmias during administration.
• Use the lowest effective dose: limit systemic exposure to reduce toxicity risk.
• Avoid concurrent use with other local anesthetics: prevents additive toxic effects.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Lidocaína Aurovitas can interact with other medicines, altering its safety profile.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may cause severe cardiotoxicity.
• Beta‑blockers: can enhance hypotensive effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely)

• Other local anesthetics: additive risk of systemic toxicity.
• General anesthetics (e.g., propofol, volatile agents): may potentiate central nervous system depression.
• Diuretics: may affect lidocaine plasma levels and renal clearance.